Emergent BioSolutions’ Board of Directors Approves Spin-Off of Aptevo Therapeutics and Sets Record and Dividend Distribution Dates and Distribution Ratio
No action or payment is required of Emergent stockholders to receive Aptevo shares. An information statement containing details of the spin-off and important information about Aptevo will be mailed to Emergent stockholders prior to the distribution date.
Trading of Emergent and Aptevo Common Stock
There is currently no market for Aptevo common stock. Aptevo expects its common stock to begin trading on a "when issued" basis shortly before the
Emergent will continue to trade on the
Stockholders who sell their shares of Emergent common stock in the "regular way" market, which is the normal trading market on the
An ex-distribution market for EBS common stock is expected to start on
The completion of the spin-off is subject to the satisfaction or waiver of a number of conditions, including Aptevo's Registration Statement on Form 10 being declared effective by the
The Registration Statement on Form 10 includes material information regarding the spin-off and Aptevo's business following the spin-off and is available at http://emergentbiosolutions.com/spinoff.
About Aptevo Therapeutics
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, without limitation, statements regarding the planned spin-off of
There are a number of important factors that could cause the company's actual results to differ materially from those indicated by such forward-looking statements, including whether the planned spin-off of Aptevo is completed, as expected or at all, and the timing of the spin-off; whether the conditions to the spin-off can be satisfied; and general market and economic conditions. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the
Robert G. BurrowsVice President, Investor Relations 240-631-3280 BurrowsR@ebsi.com Media Contact: Tracey Schmitt LintottSenior Vice President, Global Public Affairs 240-631-3394 SchmittT@ebsi.com